Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells
Authors:
- 28 November 2011
- journal article
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 33 (1) , 75-81
Abstract
Aim: Methods: Results: Conclusion:Keywords
This publication has 25 references indexed in Scilit:
- Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expressionBiochemical and Biophysical Research Communications, 2010
- Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIPBest Practice & Research Clinical Endocrinology & Metabolism, 2009
- Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent PathwaysCirculation, 2008
- Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepirideAmerican Journal of Physiology-Endocrinology and Metabolism, 2007
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesThe Lancet, 2006
- Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitusExpert Opinion on Pharmacotherapy, 2006
- The biology of incretin hormonesCell Metabolism, 2006
- Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery diseaseAmerican Journal of Physiology-Endocrinology and Metabolism, 2004
- Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive ratsJournal Of Hypertension, 2003
- AMP‐activated protein kinase phosphorylation of endothelial NO synthaseFEBS Letters, 1999